Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Marker Therapeutics (MRKR) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Marker Therapeutics (MRKR) over the last 9 years, with Q3 2025 value amounting to 1.0%.

  • Marker Therapeutics' Return on Capital Employed rose 3000.0% to 1.0% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.0%, marking a year-over-year increase of 3000.0%. This contributed to the annual value of 0.69% for FY2024, which is 500.0% down from last year.
  • According to the latest figures from Q3 2025, Marker Therapeutics' Return on Capital Employed is 1.0%, which was up 3000.0% from 1.3% recorded in Q2 2025.
  • Over the past 5 years, Marker Therapeutics' Return on Capital Employed peaked at 0.6% during Q1 2022, and registered a low of 1.3% during Q2 2025.
  • Its 4-year average for Return on Capital Employed is 0.9%, with a median of 0.83% in 2022.
  • As far as peak fluctuations go, Marker Therapeutics' Return on Capital Employed tumbled by -4800bps in 2024, and later soared by 3000bps in 2025.
  • Quarter analysis of 4 years shows Marker Therapeutics' Return on Capital Employed stood at 0.8% in 2022, then decreased by -20bps to 0.96% in 2023, then rose by 11bps to 0.86% in 2024, then decreased by -17bps to 1.0% in 2025.
  • Its last three reported values are 1.0% in Q3 2025, 1.3% for Q2 2025, and 0.77% during Q1 2025.